Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Temozolomide is an imidazotetrazine with a mechanism of action and efficacy similar to dacarbazine (DTIC). However, it differs from DTIC in that it can be taken orally, degrades spontaneously to an active metabolite and penetrates the blood-brain barrier. It is well tolerated, making it a suitable candidate for combination chemotherapy. Trials to date have focussed on its activity in advanced metastatic melanoma and high-grade malignant glioma. Investigations into other indications, in particular solid tumors with central nervous system metastases, are ongoing. Studies of new drug schedules and of drugs to ameliorate temozolomide resistance offer the prospect of increased efficacy.

Original publication

DOI

10.1586/14737140.1.1.13

Type

Journal article

Journal

Expert Rev Anticancer Ther

Publication Date

06/2001

Volume

1

Pages

13 - 19

Keywords

Administration, Oral, Antineoplastic Agents, Alkylating, Brain Neoplasms, Dacarbazine, Drug Administration Schedule, Glioma, Melanoma, Temozolomide